Suppr超能文献

与尿路感染相关的菌血症患者中抗菌药物耐药性的危险因素。

Risk factors for antimicrobial resistance in patients with bacteraemia related to urinary tract infection.

作者信息

Balfour James, Barclay Mabel, Danial Janathan, Philip Carol, Perry Meghan, Etherson Michelle, Henderson Naomi

机构信息

Clinical Infection Research Group, NHS Lothian Infection Service, Western General Hospital, United Kingdom.

出版信息

Infect Prev Pract. 2022 Sep 3;4(4):100248. doi: 10.1016/j.infpip.2022.100248. eCollection 2022 Dec.

Abstract

INTRODUCTION

NHS Lothian policy has recently changed to avoid first-line use of trimethoprim for uncomplicated urinary tract infections (UTI) in patients with risk factors for trimethoprim resistance, in line with national guidance. This study aimed to identify risk factors for antimicrobial resistance in bacteraemia related to UTI.

METHODS

A retrospective cohort study of 687 patients with bacteraemia related to UTI in NHS Lothian from 01/02/18 to 29/02/20 was undertaken. Demographics and comorbidities were collected from electronic patient records. Community prescribing and microbiology data were collected from the prescribing information system and Apex. Univariate and multivariate analysis was undertaken using RStudio to analyse trimethoprim, gentamicin and multi-drug resistance (MDR).

RESULTS

Trimethoprim resistance was present in 282/687(41%) of blood culture isolates. MDR was present in 278/687(40.5%) isolates. Previous urinary trimethoprim resistant was a significant risk factor for both trimethoprim resistance (OR 9.44, 95%CI 5.83-15.9) and MDR (OR 4.81, 95%CI 3.17-7.43) on multivariate modelling. Trimethoprim prescription (OR 2.10, 95% CI 1.33-3.34) and the number of community antibiotic courses (OR 1.19, 95%CI 1.06-1.35) were additional risk factors for trimethoprim resistance. Multiple independent risk factors were also identified for trimethoprim resistance, MDR and gentamicin resistance.

DISCUSSION

This study showed a high prevalence of trimethoprim resistance and MDR in patients with bacteraemia related to UTI. This supports the withdrawal of trimethoprim from first-line treatment of UTIs in patients with risk factors for trimethoprim resistance. It has also identified risk factors for MDR in bacteraemia.

摘要

引言

按照国家指南,NHS洛锡安地区的政策最近有所改变,对于存在甲氧苄啶耐药风险因素的患者,避免将甲氧苄啶作为单纯性尿路感染(UTI)的一线用药。本研究旨在确定与UTI相关的菌血症中抗菌药物耐药的风险因素。

方法

对2018年2月1日至2020年2月29日期间NHS洛锡安地区687例与UTI相关的菌血症患者进行回顾性队列研究。从电子病历中收集人口统计学和合并症信息。从处方信息系统和Apex收集社区处方和微生物学数据。使用RStudio进行单变量和多变量分析,以分析甲氧苄啶、庆大霉素和多重耐药(MDR)情况。

结果

在687份血培养分离株中,282份(41%)存在甲氧苄啶耐药。278份(40.5%)分离株存在MDR。多变量建模显示,既往尿培养对甲氧苄啶耐药是甲氧苄啶耐药(比值比9.44,95%置信区间5.83 - 15.9)和MDR(比值比4.81,95%置信区间3.17 - 7.43)的重要风险因素。甲氧苄啶处方(比值比2.10,95%置信区间1.33 - 3.34)和社区抗生素疗程数(比值比1.19,95%置信区间1.06 - 1.35)是甲氧苄啶耐药的其他风险因素。还确定了甲氧苄啶耐药、MDR和庆大霉素耐药的多个独立风险因素。

讨论

本研究表明,与UTI相关的菌血症患者中,甲氧苄啶耐药和MDR的发生率很高。这支持在存在甲氧苄啶耐药风险因素的患者中,不再将甲氧苄啶用于UTI的一线治疗。研究还确定了菌血症中MDR的风险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14fc/9789351/611ecdda64c2/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验